Women who take fertility drugs and do not get pregnant have a slightly reduced risk of developing breast cancer before age 50; however, those who do experience a pregnancy lasting 10 weeks or more have a slightly increased risk—one that is comparable to the risk of women who never took fertility drugs, according to the results of a study published in the Journal of the National Cancer Institute.
Breast cancer is the most commonly diagnosed type of cancer (other than skin cancer) in U.S. women. Each year, roughly 227,000 women are diagnosed with breast cancer and close to 40,000 die of the disease. Researchers continue to investigate factors that may increase or reduce the risk of breast cancer.
Fertility drugs have come under scrutiny because they stimulate hyper-ovulation, meaning they cause a woman’s body to produce more eggs. The additional eggs increase estrogen levels and estrogen has been linked to an increased risk of breast cancer.
To examine the relationship between fertility drugs and breast cancer risk, researchers conducted the Two Sister Study, a sister-matched case-control study that studied pairs of sisters. The study included 1,422 women under age 50 diagnosed with breast cancer between 2008 and 2010 and 1,669 of their sisters who had never had breast cancer.
A total of 288 women reported using one or both of the ovulation-stimulating fertility drugs clomiphene citrate (CC) and follicle-stimulating hormone (FSH) at some point and 141 women reported a pregnancy that lasted 10 weeks or more after taking the drugs. Overall, women who had taken fertility drugs had a slightly decreased risk of breast cancer compared with those who had never taken the drugs, but this risk was not considered statistically significant. Women who used fertility drugs but did not get pregnant had a statistically significantly reduced risk of breast cancer compared with non-users. Women who used fertility drugs and conceived a pregnancy that lasted 10 or more weeks showed a statistically significantly increased risk of breast cancer compared with their counterparts who took fertility drugs and did not get pregnant; however, this risk was not increased compared with women who had never used fertility drugs.
The researchers noted that there was no cause for alarm because even in the group with the increased risk after pregnancy, the risk was not higher than that of the general public.
The researchers concluded that using fertility drugs does not increase the risk of breast cancer and in fact, exposure to ovulation-stimulating fertility drugs may even reduce the risk in women who do not experience pregnancy that lasts 10 weeks or more.
Fei C, DeRoo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: Results from the Two Sister Study. Journal of the National Cancer Institute. Published early online July 6, 2012. doi: 10.1093/jnci/djs255
Fyarro for Malignant Perivascular Epithelioid Cell Tumor (PEComa)
The U.S. Food and Drug Administration (FDA) has approved FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Radiofrequency Ablation Effective For Small Kidney Cancers
Radiofrequency ablation an an effective treatment for patients with small kidney cancers.
According to the results of a study conducted in Denmark and published in the British Medical Journal, use of fertility drugs does not increase the risk of ovarian cancer.
The question of whether fertility drugs increase the risk of ovarian cancer has long been debated, and previous studies have reported mixed results. Some researchers have hypothesized that repeated, uninterrupted ovulation may contribute to the development of ovarian cancer; if this is true, it’s possible that fertility drugs could increase ovarian cancer risk by increasing ovulation. It’s also possible that some fertility drugs could have a direct carcinogenic effect on the ovary.
To evaluate the relationship between fertility drugs and risk of ovarian cancer, researchers in Denmark conducted a study among more than 54,000 women who were referred to fertility clinics between 1963 and 1998. The researchers compared the risk of ovarian cancer among the women who used fertility drugs to the risk among women who did not use fertility drugs.
The types of fertility drugs that were evaluated were gonadotropins (follicle stimulating hormone and human menopausal gonadotropins), clomifene citrate, human chorionic gonadotropins, and gonadotropin releasing hormone. Clomifene was the most commonly used drug.
After a median of 16 years of follow-up, 156 women had developed ovarian cancer. Overall, the risk of ovarian cancer was similar among women who had and had not used fertility drugs.
The researchers also analyzed the effects of fertility drugs on specific types of ovarian cancer (serous, endometrioid, mucinous, clear cell, and other). The results suggested that clomifene may increase the risk of serous cancers.
The researchers concluded that “No convincing association was found between use of fertility drugs and risk of ovarian cancer.” They will continue to follow the study participants, however, because many of the women have not yet reached the peak ages for ovarian cancer.
Reference: Jensen A, Sharif H, Frederiksen K, Krüger Kjaer S. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. British Medical Journal [early online publication]. February 5, 2009.
Copyright © 2018 CancerConnect. All Rights Reserved.